A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Research Article

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

	Abstract	Full	Pdf
Dec 2019	1	1	0
Jan 2020	6	6	2
Feb 2020	5	5	2
Mar 2020	7	7	0
Apr 2020	12	12	6
May 2020	14	14	1
Jun 2020	13	13	0
Jul 2020	13	13	4
Aug 2020	1	1	0
Sep 2020	17	17	1
Oct 2020	19	19	3
Nov 2020	11	10	3
Dec 2020	5	5	3
Jan 2021	8	8	3
Feb 2021	11	11	5
Mar 2021	8	8	2
Apr 2021	3	3	0
May 2021	10	10	0
Jun 2021	7	7	0
Jul 2021	12	12	2
Aug 2021	1	1	1
Sep 2021	4	4	1
Oct 2021	9	9	3
Nov 2021	10	10	1
Dec 2021	17	17	3
Jan 2022	8	9	2
Feb 2022	5	5	2
Mar 2022	58	58	1
Apr 2022	57	58	5
May 2022	84	84	0
Jun 2022	53	53	1
Jul 2022	43	44	3
Aug 2022	45	45	0
Sep 2022	52	52	2
Oct 2022	51	51	0
Nov 2022	43	45	11
Dec 2022	40	40	0
Jan 2023	19	19	2
Feb 2023	37	37	0
Mar 2023	35	36	2
Apr 2023	38	38	2
May 2023	33	33	2
Jun 2023	25	25	0
Jul 2023	42	42	10
Aug 2023	45	45	3
Sep 2023	45	45	7
Oct 2023	35	35	3
Nov 2023	40	40	1
Dec 2023	54	54	2
Jan 2024	13	14	7
Feb 2024	21	21	2
Mar 2024	4	4	3
Total	1249	1255	119